

REMARKS/ARGUMENTS

The claims have been divided into Groups as follows:

Group I: Claims 40 and 51-53, drawn to a compound/composition comprising a compound.

Group II: Claims 1-39 and 41-48, drawn to a method for treating or preventing a disease.

Additionally, if either Group I or II is elected, applicants have been required to elect a single disclosed compound specie as follows: (i) for example, a compound from the compounds recited in claims 43-45, or a compound disclosed in the specification (e.g., pages 49-72).


Applicants elect, without traverse, Group I, Claims 40 and 51-53 (drawn to a compound/composition comprising a compound), for examination.

Applicants also provisionally elect, without traverse and for examination purposes only, the following specie of compound: 1-(2-cyclohexyl-ethyl)-3-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-urea (compound No. 16 on page 50 of the specification) (claims 51-53 readable thereon).

Applicants respectfully submit that the above-identified application is now in condition for examination on the merits, and early notice thereof is earnestly solicited.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

  
Justine M. Wilbur  
Registration No. 59,678

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 08/07)